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While the beneﬁts of gastric bypass (GB)
surgery in type 2 diabetes are well es-
tablished, few studies have evaluated
the long-term effects of GB in patients
with type 1 diabetes (1,2), and these
studies demonstrate conﬂicting effects
on glycemic control. This is clinically im-
portant given the increasing prevalence
of obesity in patients with type 1 diabe-
tes (3). We studied 10 severely obese
women with conﬁrmed type 1 diabetes,
as previously described (4), and evalu-
ated outcomes prior to GB and at 1
and 5 years following surgery. Mean
age at GB was 39.6 6 8.4 years, mean
duration of type 1 diabetes 24.66 10.1
years, and mean age at diagnosis 16.06
8.3 years. Six subjects used continuous
subcutaneous insulin infusion.
BMI decreased by 33% from baseline
at 1 year postoperatively (from 43.5 6
7.5 to 29.36 5.4 kg/m2, P, 0.0001) but
increased by a mean of 15% (to 33.8 6
7.5 kg/m2, P , 0.01) from 1 to 5 years
(Table 1). Compared with baseline,
HbA1c was unchanged at 1 year (baseline
8.1 6 1.3% [65 6 14.2 mmol/mol] to
1 year 8.36 1.4% [676 15.3 mmol/mol],
P 5 0.47). Interestingly, HbA1c trended
upward at 5 years postoperatively to
9.8 6 1.9% (84 6 20.8 mmol/mol, P 5
0.15). Basal insulin requirements decreased
from 53.06 29.7 to 23.06 15.6 units/day
(P 5 0.0005) at 1 year postoperatively
but trended up from 1 to 5 years to
31.1 6 22.8 units/day (P 5 0.17). The
trend held even when accounting for
body weight. There was a robust corre-
lation between change in insulin dose
and weight (r 5 0.66; P 5 0.04).
Cardiometabolic risk factor assess-
ment showed decreases in plasma tri-
glycerides (28% decrease, P 5 0.004)
and systolic blood pressure (mean de-
crease of 11 6 8.3 mmHg, P 5 0.003)
at 1 year; however, these decreases were
not sustained at 5 years. There was no
signiﬁcant change in diastolic blood pres-
sure, total cholesterol, or LDL. Interest-
ingly, HDL increased by 22% from 1 to 5
years following GB surgery (P 5 0.004).
Despite limited data on diabetes-related
complications, microalbuminuria tended
to improve, though this was largely
driven by one subject. One subject had
severe nonproliferative diabetic retinop-
athy (NPDR) at baseline, which improved
to moderate NPDR at 1-year follow-up;
moderate NPDR was unchanged in two
subjects 1 year postoperatively.
We conclude that GB does not im-
prove long-term glycemic control in se-
verely obese women with type 1
diabetes. However, GB reduced body
weight and improved several cardiome-
tabolic risk factors for up to 5 years fol-
lowing surgery. The lack of sustained
effect of GB on glycemic control in
individuals with type 1 diabetes is
likely a consequence of their persistent
absolute insulin requirement, resulting
in periods of fasting hyperglycemia and
increased variability of postprandial glu-
cose excursions, as previously demon-
strated in subjects with type 2 diabetes
after GB (5). GBmarkedly alters patterns
of early postprandial glycemia, contrib-
uting to a potential mismatch between
nutrient absorption and prandial insulin
timing.
Our studywas limited by small sample
size and single-sex cohort. Nevertheless,
our evaluation of anthropometric, gly-
cemic, and cardiometabolic outcomes
at multiple time points following GB sur-
gery in severely obese women with
type 1 diabetes suggests that GB induces
weight loss and improvement of some
cardiovascular risk factors but does not
improve long-term glycemic control in
women with type 1 diabetes.
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Table 1—Anthropometric and cardiometabolic risk factors and glycemic control at baseline (n 5 10) and at 1 (n 5 10) and 5
(n 5 7) years following GB surgery
Baseline 1 year P value† 5 years P value‡ P value§
Weight (kg) 121.9 6 22.1 81.9 6 15.8 ,0.0001** 93.6 6 21.0 ,0.0001** ,0.01*
BMI (kg/m2) 43.5 6 7.5 29.3 6 5.4 ,0.0001** 33.8 6 7.5 ,0.0001** ,0.01*
HbA1c (%) 8.1 6 1.3 8.3 6 1.4 0.47 9.8 6 1.9 0.15 0.26
HbA1c (mmol/mol) 65 6 14.2 67 6 15.3 0.47 84 6 20.8 0.15 0.26
Basal insulin (units/day) 53.0 6 29.7 23.0 6 15.6 0.0005** 31.1 6 22.8 0.02* 0.17
Basal insulin (units/kg/day) 0.42 6 0.19 0.27 6 0.13 0.0005** 0.37 6 0.17 0.0021* 0.174
Insulin pump, n (%) 6 (60) 6 (60) 5 (71)
Multiple daily injections, n (%) 4 (40) 4 (40) 2 (29)
Systolic blood pressure (mmHg) 123.6 6 8.3 112.6 6 11.3 0.003* 118.7 6 14.1 0.45 0.19
Diastolic blood pressure (mmHg) 72.8 6 8.3 69.7 6 4.2 0.32 72.4 6 7.2 0.97 0.57
HDL (g/dL) 61.5 6 18.4 63.0 6 11.8 0.8 80.5 6 16.7 0.04* 0.004*
LDL (g/dL) 102.3 6 20.4 92.8 6 20.5 0.41 91.5 6 26.3 0.44 0.95
Total cholesterol (g/dL) 185.4 6 30.9 172.7 6 24.2 0.59 195.3 6 27.5 0.72 0.07
Triglycerides (g/dL) 112.8 6 55.1 80.6 6 43.6 0.004* 111.2 6 109.5 0.12 0.29
Microalbumin (mg/L) 62.2 6 142 21.5 6 26.7 0.34 14.2 6 16.3 0.29 0.07
Data are presented as mean6 SD, unless otherwise noted. †1 year compared with baseline. ‡5 years compared with baseline. §5 years compared
with 1 year. *Signiﬁcant at P , 0.05. **Signiﬁcant at P , 0.001.
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